featured
6 vs 12 Months of Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
6 Versus 12 Months of Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer (PERSEPHONE): 4-Year Disease-Free Survival Results of a Randomised Phase 3 Non-Inferiority Trial
Lancet 2019 Jun 06;[EPub Ahead of Print], HM Earl, L Hiller, AL Vallier, S Loi, K McAdam, L Hughes-Davies, AN Harnett, ML Ah-See, R Simcock, D Rea, S Raj, P Woodings, M Harries, D Howe, K Raynes, HB Higgins, M Wilcox, C Plummer, J Mansi, I Gounaris, B Mahler-Araujo, E Provenzano, A Chhabra, JE Abraham, C Caldas, PS Hall, C McCabe, C Hulme, D Miles, AM Wardley, DA Cameron, JA DunnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.